Cargando…
Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
The first case of SARS-CoV-2 infection was reported in December 2019. Due to the rapid spread of the disease and the lack of adequate therapy, the use of plants that have a long history in the treatment of viral infections has often been considered. The aim of this paper is to provide a brief review...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686831/ https://www.ncbi.nlm.nih.gov/pubmed/36421257 http://dx.doi.org/10.3390/antibiotics11111614 |
_version_ | 1784835851393433600 |
---|---|
author | Bijelić, Katarina Hitl, Maja Kladar, Nebojša |
author_facet | Bijelić, Katarina Hitl, Maja Kladar, Nebojša |
author_sort | Bijelić, Katarina |
collection | PubMed |
description | The first case of SARS-CoV-2 infection was reported in December 2019. Due to the rapid spread of the disease and the lack of adequate therapy, the use of plants that have a long history in the treatment of viral infections has often been considered. The aim of this paper is to provide a brief review of the literature on the use of phytochemicals during the new pandemic. An extensive search of published works was performed through platforms Google Scholar, PubMed, Science Direct, Web of Science and Clinicaltrials.gov. Numerous preclinical studies on the use of phytochemicals (quercetin, curcumin, baicalin, kaempferol, resveratrol, glycyrrhizin, lycorine, colchicine) against SARS-CoV-2 have shown that these components can be effective in the prevention and treatment of this infection. Clinical research has proven that the use of black cumin and green propolis as well as quercetin has positive effects. As for other phytochemicals, in addition to preclinical testing which has already been carried out, it would be necessary to conduct clinical tests in order to assert their effectiveness. For those phytochemicals whose clinical efficacy has been proven, it would be necessary to conduct research on a larger number of patients, so that the conclusions are more representative. |
format | Online Article Text |
id | pubmed-9686831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96868312022-11-25 Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence Bijelić, Katarina Hitl, Maja Kladar, Nebojša Antibiotics (Basel) Review The first case of SARS-CoV-2 infection was reported in December 2019. Due to the rapid spread of the disease and the lack of adequate therapy, the use of plants that have a long history in the treatment of viral infections has often been considered. The aim of this paper is to provide a brief review of the literature on the use of phytochemicals during the new pandemic. An extensive search of published works was performed through platforms Google Scholar, PubMed, Science Direct, Web of Science and Clinicaltrials.gov. Numerous preclinical studies on the use of phytochemicals (quercetin, curcumin, baicalin, kaempferol, resveratrol, glycyrrhizin, lycorine, colchicine) against SARS-CoV-2 have shown that these components can be effective in the prevention and treatment of this infection. Clinical research has proven that the use of black cumin and green propolis as well as quercetin has positive effects. As for other phytochemicals, in addition to preclinical testing which has already been carried out, it would be necessary to conduct clinical tests in order to assert their effectiveness. For those phytochemicals whose clinical efficacy has been proven, it would be necessary to conduct research on a larger number of patients, so that the conclusions are more representative. MDPI 2022-11-13 /pmc/articles/PMC9686831/ /pubmed/36421257 http://dx.doi.org/10.3390/antibiotics11111614 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bijelić, Katarina Hitl, Maja Kladar, Nebojša Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence |
title | Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence |
title_full | Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence |
title_fullStr | Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence |
title_full_unstemmed | Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence |
title_short | Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence |
title_sort | phytochemicals in the prevention and treatment of sars-cov-2—clinical evidence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686831/ https://www.ncbi.nlm.nih.gov/pubmed/36421257 http://dx.doi.org/10.3390/antibiotics11111614 |
work_keys_str_mv | AT bijelickatarina phytochemicalsinthepreventionandtreatmentofsarscov2clinicalevidence AT hitlmaja phytochemicalsinthepreventionandtreatmentofsarscov2clinicalevidence AT kladarnebojsa phytochemicalsinthepreventionandtreatmentofsarscov2clinicalevidence |